RFK Jr. eases access to unproven peptides despite opposition from FDA scientists
HHS issued an interim enforcement policy for compounding certain peptide substances while formal rulemaking continues.
TL;DR
- HHS published an interim policy describing when it would exercise enforcement discretion for certain compounded peptides.
- The policy concerns pharmacy compounding and does not make the substances FDA-approved drugs.
- The Associated Press reported that FDA scientific staff opposed the policy approach and had limited input in its development.
The Federal Register notice describes an HHS enforcement-discretion policy for certain peptide bulk drug substances compounded under section 503A while a formal list is developed. [1]
The Associated Press reported that the administration’s policy would ease access to some peptides through compounding pharmacies and that FDA scientists had opposed the change. The report attributed internal deliberations to people familiar with the process. [2]
The Washington Post also reported staff opposition and described the policy’s development. The policy is an enforcement approach; it does not establish that compounded products are FDA-approved or that their safety and effectiveness have been reviewed. [3]
The Federal Register states that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Implementation details and the eventual rulemaking outcome remain open. [1]
Why it matters
The policy changes the regulatory environment for certain compounded peptide substances while the formal rulemaking process continues. The distinction between enforcement discretion and FDA approval is central to understanding its scope.
Editor's note
Regulatory reporting only. Compounded products are not FDA-approved; no wellness framing, product recommendation or use guidance is included.